

Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

HealthTech guidance

Published: 27 September 2023

www.nice.org.uk/guidance/htg695

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Contents

1 Recommendations	4
Evidence generation	5
2 The technologies.....	8
Care pathway	10
The comparators	10
3 Committee discussion	11
Unmet need and potential value.....	11
Clinical effectiveness	12
Cost and resource use.....	13
Implementation.....	14
Equality considerations	15
Evidence gap review.....	16
4 Committee members and NICE project team.....	19
Committee members	19
Specialist committee members	19
NICE project team	20
Update information	21

This guidance replaces HTE11.

1 Recommendations

- 1.1 Nine artificial intelligence (AI) technologies can be used in the NHS while more evidence is generated to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy. AI technologies must be used with healthcare professional review of contours.

The following technologies can only be used once they have Digital Technology Assessment Criteria (DTAC) approval:

- AI-Rad Companion Organs RT (Siemens Healthineers)
- ART-Plan (TheraPanacea, Oncology Systems; Brainlab)
- DLCExpert (Mirada Medical)
- INTContour (Carina Medical)
- Limbus Contour (Limbus AI, AMG Medtech)
- MIM Contour ProtégéAI (MIM Software)
- MRCAT Prostate plus Auto-contouring (Philips)
- MVision Segmentation Service (MVision AI Oy, Xiel)
- RayStation (RaySearch).

- 1.2 The technology developers or companies must confirm that agreements are in place to generate the evidence (as outlined in [NICE's evidence generation plan](#)) and contact NICE annually to confirm that evidence is being generated and analysed as planned. NICE may withdraw the guidance if these conditions are not met.

- 1.3 At the end of the evidence generation period (3 years, or sooner if sufficient evidence is available), the technology developers or companies should submit

the evidence to NICE in a form that can be used for decision making. NICE will review the evidence and assess if the technologies can be routinely adopted in the NHS.

Evidence generation

1.4 More evidence needs to be generated on the following key outcomes:

- clinical acceptability of contours and amount of edits needed
- impact of AI autocontouring on radiation dose to organs at risk (OAR) and the tumour
- time saving including time for healthcare professional review and edits
- resource use defined by healthcare professional grade and time
- contouring errors and adverse events associated with AI autocontouring.

Potential benefits of early use

- **System benefit:** AI technologies may help healthcare professionals to produce contours more quickly. This may make the workflow more efficient. It may also improve the consistency of contours and increase compliance with national and international guidelines.
- **Clinical benefit:** Clinical evidence suggests that AI technologies generally produce similar quality contours as manual contouring, with most structures needing only minor edits.
- **Resources:** The evidence suggests that AI autocontouring is quicker than manual contouring even when including time for healthcare professional review and edits. This could have potential cost savings. It may also free up healthcare professional time for patient-facing tasks or more complex cases when AI autocontouring may not be appropriate.

Managing the risk of early use

- **Clinical review:** All AI autocontours must be reviewed and edited as needed by a trained healthcare professional before being used in radiotherapy treatment planning.
- **Costs:** Potential cost savings depend on technology costs including setup and maintenance, time saving and the healthcare professional grade of the person doing the contouring. With a band 7 radiographer doing the contouring, cost analysis suggests that the highest priced AI technology (£50 per plan) would need to save around 47 minutes to be cost neutral, compared with 4 minutes for the lowest priced technology (£4 per plan). This guidance will be reviewed within 3 years, or sooner if sufficient evidence is available and the recommendations may change. Take this into account when negotiating the length of contracts and licence costs.
- **Information governance:** NHS hospitals and trusts should have appropriate information governance policies for using AI technologies.
- **Equality:** AI models can contain algorithmic bias depending on the population used in training, which may not be representative of populations in clinical

practice. This may affect the performance of AI autocontouring for some populations such as children and young people, or people with atypical anatomy.

The evidence generation plan gives further information on the prioritised evidence gaps and outcomes, ongoing studies and potential real-world data sources. It includes how the evidence gaps could be resolved through real-world evidence studies.

2 The technologies

- 2.1 Contouring is an important part of the radiotherapy treatment planning process. It involves outlining the target volumes and organs at risk (OAR) to guide radiotherapy so that treatment is effective and radiation toxicity is minimised. Artificial intelligence (AI) technologies aim to improve contouring efficiency by automatically contouring the OAR and sometimes the target volumes before radiotherapy. The technologies have been trained to process images from CT, cone-beam CT or MRI scans to produce an initial contour. Images and contours are then reviewed by trained healthcare professionals and modified as needed before use.
- 2.2 NICE has assessed 11 AI technologies to aid contouring for radiotherapy treatment planning. The criteria for including technologies in this assessment are in the final scope in the [project documents for this guidance](#). Nine technologies have regulatory approval for use in the NHS:
- AI-Rad Companion Organs RT (Siemens Healthineers) is a standalone software that contours over 60 OAR structures on CT scans including the abdomen, head and neck, pelvis and thorax.
 - ART-Plan (TheraPanacea, Oncology Systems; Brainlab) is a standalone software that contours over 150 structures including OAR and lymph nodes in the abdomen, brain, head and neck, thorax and pelvis on CT images and the abdomen, brain and male pelvis on MRI scans.
 - DLCExpert (Mirada Medical) is deployed on Mirada Medical's Workflow Box platform. It contours over 160 structures on CT and MRI images, including the abdomen, breast, head and neck, prostate and thorax.
 - INTContour (Carina Medical) is a standalone software that contours over 60 target and OAR structures from the abdomen, head and neck, male pelvis and thorax.
 - Limbus Contour (Limbus AI, AMG Medtech) is a standalone software that contours over 200 OAR and target volumes including lymph nodes, the abdomen, breast, central nervous system, head and neck, lungs, pelvis and

prostate on CT images, and the central nervous system, gynaecological and brachy structures on MRI scans.

- MIM Contour ProtégéAI (MIM Software) is a standalone software that contours the head and neck, thorax, lungs and liver, prostate and abdomen structures from CT images and the prostate from MRI scans.
- MRCAT Prostate plus Auto-contouring (Philips) is a clinical application integrated in the Philips MR-RT systems for MRI in radiation therapy. It provides automatic contours of the prostate and associated OAR.
- MVision Segmentation Service (MVision AI Oy, Xiel) is a standalone software that contours over 160 structures including OAR and target volumes in the abdomen and thorax, brain, breast, head and neck, and pelvis.
- RayStation (RaySearch) is a radiotherapy external beam and brachytherapy planning system with AI autocontouring functionality. It contours over 70 structures on CT images including the breast and lymph nodes, head and neck, male pelvis, thorax and abdomen.

Two technologies are awaiting CE or UK Conformity Assessed (UKCA) mark approval so cannot be used yet:

- AutoContour (Radformation) is a standalone software that contours over 200 structures including OAR and lymph nodes in the chest and abdomen, head and neck, and pelvis on CT images and the brain on MRI scans.
- OSAIRIS (Cambridge University Hospitals NHS Foundation Trust) is an open-source standalone software that contours up to 26 head and neck and prostate treatment site structures on CT images.

The Medicines and Healthcare products Regulatory Agency (MHRA) advised that most AI autocontouring technologies will likely be classified as class IIa or higher under the [MHRA guidance on software as a medical device](#). The government has [extended the transition period for CE marked devices in the UK](#).

Care pathway

- 2.3 The [National Cancer Registration and Analysis Service \(NCRAS\)](#) and [Cancer Research UK \(CRUK\) statistics on chemotherapy, radiotherapy and surgical tumour resections in England](#) reported that between 2013 and 2019, about 40% of people with cancer had radiotherapy as part of their cancer treatment. Clinical experts advised that AI technologies could be used to aid contouring for everyone having external beam radiotherapy.
- 2.4 Manual contouring is the most common contouring method in standard care. Manual contouring of target regions is usually done by clinical oncologists. Contouring of OAR may also be done by clinical technologists, dosimetrists or therapeutic radiographers. There are guidelines and consensus statements on contouring from organisations such as the [European Society for Radiotherapy and Oncology](#), the [Global Quality Assurance of Radiation Therapy Clinical Trials Harmonization Group](#) and the [Royal College of Radiologists](#). Other contouring methods include atlas-based contouring and model-based segmentation, but these are not as widely used. Regardless of contouring method, contours should be reviewed before being used in treatment planning in line with guidance such as the [Royal College of Radiologists guidance on radiotherapy target volume definition and peer review](#).
- 2.5 AI technologies would be used to provide an initial contour as part of the standard workflow for radiotherapy treatment planning. AI autocontours would then be reviewed by trained healthcare professionals and edited as needed before being used in treatment planning.

The comparators

- 2.6 Comparators are contouring methods used in standard care to contour OAR and target volumes. These include manual contouring, atlas-based contouring and model-based segmentation. Comparators may also include no contouring for cases when AI technologies may produce contours for structures not routinely contoured in standard care.

3 Committee discussion

NICE's [medical technologies advisory committee](#) considered evidence on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning from several sources, including an early value assessment (EVA) report by the external assessment group (EAG), and an overview of that report. Full details are in the [project documents for this guidance](#).

Unmet need and potential value

- 3.1 AI autocontouring with healthcare professional review may be quicker than other contouring methods, which could reduce healthcare professional time to do contouring. This could reduce costs and increase efficiency, which may increase capacity, allow more focus on patient-facing tasks and reduce waiting lists. The Royal College of Radiologists clinical oncology census report 2021 reported workforce pressure because of staff shortages and continued effects from the COVID-19 pandemic. Clinical experts advised that they spend a lot of time creating and reviewing manual contours. They said that healthcare professionals have reported finding it easier to review and edit AI autocontours than to create contours from scratch.
- 3.2 Clinical experts advised that AI technologies could improve the consistency of contours and compliance with national and international guidelines. Some AI technologies have been trained using guidelines and may be regularly updated when guidelines update. One expert said that AI technologies helped improve how they were defining structures and may produce smoother contours of 3D structures than manual contouring. AI technologies may also produce contours for structures not routinely contoured in standard care. This could improve treatment planning and quality of care.

Clinical effectiveness

Potential benefits

- 3.3 The committee considered that there was strong evidence for the potential usefulness of AI technologies to aid contouring in radiotherapy treatment planning. The relevant evidence consisted of 79 studies, including 27 full-text publications and 52 conference abstracts. Because of the large number of publications, the EAG extracted data from 15 prioritised studies, specifically:
- 8 prospective studies (DLCExpert, Limbus Contour, MIM Contour ProtégéAI and MRCAT Prostate plus Auto-contouring)
 - 4 retrospective studies (INTContour, MVision Segmentation Service, OSAIRIS, RayStation)
 - 1 mixed retrospective and prospective study (AI-Rad Companion Organs RT)
 - 2 conference abstracts (ART-Plan, AutoContour).

The evidence base for each technology and the EAG's rationale for selecting the prioritised studies are outlined in the assessment report in the [project documents for this guidance](#). The level of evidence varied across technologies, but all technologies had some evidence showing potential benefits of AI autocontouring. Overall, the clinical evidence showed that AI autocontours were generally similar to manual contours, with most rated as clinically acceptable and ready to use or needing only minor edits. AI autocontouring was also consistently quicker than manual contouring even when including time for healthcare professional review and edits. The committee concluded that AI autocontouring with healthcare professional review and edits was likely to be clinically equivalent to manual contouring and quicker to do.

Differences in performance

- 3.4 The evidence showed that although AI autocontouring worked well for most organs at risk (OAR) and clinical target volumes, there were some structures that

needed major edits or were unusable. These were typically smaller structures such as the cochlea, optic chiasm, optic nerve, penile bulb and pituitary gland. The clinical experts advised that AI autocontouring performed similarly in clinical practice. AI technologies sometimes have difficulties contouring very small or irregularly shaped organs. AI autocontours may also be less accurate for people with atypical anatomy or who have trouble with positioning during imaging. One expert estimated that for head and neck structures, about 90% to 95% of AI autocontours would be accurate. The clinical experts noted that over time, healthcare professionals learn where specific AI technologies produce less accurate contours. This means they can make edits more quickly because they know that certain areas of the contour are likely to need editing.

Cost and resource use

3.5 Cost-consequence analysis showed that potential cost saving from using AI autocontouring as an alternative to manual contouring depended on technology costs, time saving and healthcare professional grade of the person doing the contouring:

- Technology costs ranged from £4 to £50 per plan and included software (licence and subscription), hardware, data storage, and upgrade and maintenance costs. Several companies advised that healthcare professional training is also included in these costs.
- The clinical evidence reported time savings ranging from 3 minutes to 80 minutes, but the EAG advised that these savings did not always include the time for healthcare professional review and edits. The clinical experts estimated time saving of 10 minutes to 30 minutes depending on the amount of editing needed. The committee noted the importance of clinical acceptability of the AI autocontours because this may affect the number of edits needed when reviewed by a healthcare professional.
- Experts advised that contouring of OAR may be done by band 6 or 7 radiographers or speciality training doctors if there are not enough radiographers. Contours are usually reviewed by consultant clinical oncologists. But there may be many people involved in the review and sign-off of contours, which may make it difficult to estimate true resource use.

3.6 The simple cost offset calculator showed that as technology costs increased, the time saving needed for AI technologies to be cost saving or cost neutral also increased. The same was found for healthcare professional grade needed to do manual contouring. For example:

- With the lowest technology cost of £4 per plan and a band 7 radiographer (£65 per hour based on [PSSRU Unit Costs of Health and Social Care 2021](#)) doing the contouring, time saved would need to be around 4 minutes for the AI technology to be cost neutral.
- With the highest technology cost of £50 per plan and a band 7 radiographer doing the contouring, the time saved must be around 47 minutes for the AI technology to be considered cost neutral.

The EAG advised that there were several factors in the analysis that may cause a wide variation in results. It noted that the limited cost-effectiveness evidence made it difficult to draw firm conclusions about the potential cost effectiveness of the time saving compared with manual contouring. Estimates of healthcare professional costs may also vary depending on the source used. The committee concluded that although there were uncertainties in the cost analysis, AI technologies were likely to be cost saving or cost neutral but this largely depended on the technology costs and time saving.

Implementation

Managing risk

3.7 AI technologies would be used to aid contouring for radiotherapy treatment planning within the existing care pathway. AI autocontours must always be reviewed by trained healthcare professionals and edited as needed before being used. There were no adverse events reported in the evidence or by the clinical experts. So, the committee considered that the risk of AI autocontouring with healthcare professional review and edits is likely to be low. People having contouring should be made aware that AI technologies are being used, and the role of healthcare professionals in the radiotherapy treatment planning process should be explained. Some technology developers or companies said they have

tools that healthcare professionals can use to report errors in the performance and outputs of their technology. The committee concluded that there should be ongoing reporting of any errors in AI autocontouring and adverse events associated with these technologies.

- 3.8 NHS hospitals and trusts should have appropriate information governance policies for using AI technologies. AI technologies must also have national and local Digital Technology Assessment Criteria (DTAC) approval before being used in clinical practice.
- 3.9 In the future, more widespread use of these technologies could result in a skill loss in the workforce. Clinical experts advised that healthcare professionals would nearly always do some editing as part of their review of the autocontours. The committee considered that it is important for healthcare professionals to develop and to maintain contouring skills so they could adequately review and edit AI autocontours. Some technologies provided training packages for healthcare professionals to develop and practise their skills.

Technical considerations

- 3.10 The committee considered that the compatibility of AI technologies with current systems may vary in each NHS hospital or trust. Most technologies were identified as being available to work with any system and so should have minimal technical implementation issues. The experts advised that AI technologies should be compatible with existing hospital systems if they use the DICOM (Digital Imaging and Communications in Medicine) format.

Equality considerations

- 3.11 AI models can contain algorithmic bias depending on the population used in training, which may not be representative of populations in clinical practice. This may cause bias based on age, disability, sex and geographical location. Experts advised that there may be a lack of representation of female pelvis and breast cancer in men in some training datasets. Training datasets may also underrepresent children and young people.

- 3.12 AI technologies used to aid contouring may work best with certain CT or MRI sequences or with the person being in a specific position. Training datasets may not include data on atypical positioning or atypical anatomy, for example, if someone has had a previous surgery. This may affect how well AI autocontouring works for these populations. Healthcare professionals may consider manual contouring to be more appropriate for some people because it may produce more accurate contours in these specific cases. This is not thought to affect patient care or outcomes but may affect time to produce, review and edit contours.
- 3.13 Risk of bias should be considered as part of a local assessment process when deciding if to use AI technologies. Technology developers or companies should provide information on training datasets as part of their product information pack, including demographics of population datasets. Clinical experts advised that most AI technologies were not retrained on local training sets although some had the capacity for this. Ideally in the future AI technologies could be trained on a representative national population.

Evidence gap review

- 3.14 For all technologies, evidence gaps can be related to the population, the intervention, or the main outcomes. The committee concluded that there was enough evidence of potential benefits from the 9 technologies for them to be used in the NHS once they have DTAC approval, while further evidence is generated to address these gaps. Two other technologies also had evidence of potential benefits but these are awaiting CE or UK Conformity Assessed (UKCA) mark approval so cannot be used yet. Important evidence gaps for all technologies are:
- **Population:** the most assessed anatomical sites were the head and neck, and pelvis or prostate. More evidence is needed on how well AI autocontouring works in different anatomical sites. There was no relevant published evidence on using AI autocontouring in specific population groups, such as children and young people or people with atypical anatomy because of surgery. The committee considered that the demographics of datasets used for training an algorithm may differ from populations in clinical settings. It highlighted the need for evidence generation on how AI technologies work in clinical practice

in local populations, including information on population demographics such as age, sex, disability and ethnicity.

- **Intervention:** there were 2 technologies (ART-Plan and AutoContour) with no full-text evidence.
- **Outcomes:** only 4 technologies (DLCExpert, INTContour, Limbus Contour and RayStation) had evidence that included dosimetric analysis. The committee highlighted the need for further evidence on dosimetric analysis in other technologies. In all technologies there was a need for long-term patient outcomes and data on adverse events including the impact of AI autocontouring on radiation toxicity. There were 6 technologies (AI-Rad Companion Organs RT, DLCExpert, Limbus Contour, MIM Contour ProtégéAI, MVision Segmentation Service, OSAIRIS) that had evidence on the time saved using AI technologies compared with atlas-based or manual contouring. Time saved was highlighted as a key potential benefit of these technologies. The committee highlighted the importance for evidence generation in timesaving to include time for healthcare professional review and edits after AI technology use. Clinician acceptability and number of edits needed for AI autocontouring may impact overall time saved and so should be accounted for. The committee also noted that the time and cost saving potential is impacted by who edits the contour. So, any evidence generated should include healthcare professional grade and the impact of this on time and cost saving.

3.15 In addition to the key outcomes listed in [section 1.4](#), the committee agreed that real-world evidence on using AI autocontouring in clinical practice could provide more valuable information about:

- accuracy and acceptability of autocontours across a range of anatomical sites
- how well AI technologies work in an NHS population, including people with limited mobility or atypical anatomy
- the frequency of software updates and impact of updates on how well AI autocontouring works.

In the longer term, evidence on patient outcomes such as radiation toxicity

and survival outcomes could become available.

4 Committee members and NICE project team

Committee members

This topic was considered by NICE's medical technologies advisory committee, which is a standing advisory committee of NICE.

Committee members are asked to declare any interests in the technologies to be evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

The minutes of the medical technologies advisory committee meetings, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Specialist committee members

Additional specialist committee members took part in the discussions and provided expert advice for this topic:

Dr Angela Pathmanathan

Consultant clinical oncologist, Royal Marsden NHS Foundation Trust

Dr Carl Rowbottom

Consultant clinical scientist and director of physics, Clatterbridge Cancer Centre NHS Foundation Trust

Dr David Bernstein

Lead physicist in radiotherapy imaging, Royal Marsden NHS Foundation Trust

Dr Jacqueline Poxon

Deputy head of treatment planning physics, Barts Health NHS Trust

Mr Mayur Munshi

Lead for dosimetry, Beatson West of Scotland Cancer Centre

Dr Samantha Warren

Consultant clinical scientist, Newcastle upon Tyne University Hospitals NHS Trust

Mr Syed Moinuddin

Lead research and development radiographer, University College London Hospitals (UCLH) NHS Foundation Trust

Dr Teresa Guerrero Urbano

Consultant clinical oncologist and adjunct reader, Guy's and St Thomas's NHS Foundation Trust and King's College London

NICE project team

Each medical technologies guidance topic is assigned to a team consisting of 1 or more health technology assessment analysts (who act as technical leads for the topic), a health technology assessment adviser and a project manager.

Dionne Bowie and Alice Bell

Health technology assessment analyst and associate health technology assessment analyst

Bernice Dillon

Health technology assessment adviser

Elizabeth Islam

Project manager

Update information

Minor changes since publication

December 2025: Health technology evaluation 11 has been migrated to HealthTech guidance 695. The recommendations and accompanying content remain unchanged.

ISBN: 978-1-4731-7708-6